ArticleMedicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents2026
Siderophore-Porphyrin conjugates for bacteria-selective antimicrobial photodynamic therapy.
Article in Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Targeted delivery of photosensitizers represents a key strategy for improving the selectivity and efficacy of antimicrobial photodynamic therapy (aPDT). Herein, we describe the synthesis and biological evaluation of siderophore-conjugated photosensitizers designed to exploit bacterial iron acquisition pathways. Four distinct photosensitizers-neutral porphyrin (TPP), cationic porphyrin (TMPyP), metalloporphyrin (PdTMPyP), and chlorin (Ce6)-were covalently linked to deferoxamine B (DFO), a clinically approved hydroxamate siderophore. The resulting conjugates retained their intrinsic photophysical properties while exhibiting iron-dependent antimicrobial activity against siderophore-utilizing pathogens. TMPyP-DFO (3) was determined as the best compound, demonstrating potent antimicrobial photodynamic activity against Staphylococcus aureus and Acinetobacter baumannii under iron-deficient conditions (MIC
Indexed as
Identifiers
42446723What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.